Polymeric oncolytic adenovirus for cancer gene therapy.
Polymeric oncolytic adenovirus for cancer gene therapy.
复制标题
DOI：
10.1016/j.jconrel.2015.10.009
复制
发表时间：
2015-12-10
期刊：
影响因子：
--
通讯作者：
Kim SW
中科院分区：
文献类型：
--
作者：
Choi JW;Lee YS;Yun CO;Kim SW
溶瘤腺病毒（Ad）载体呈现出治疗癌症的有希望的模式。许多临床试验已经用裸溶瘤Ad或与化学疗法的组合进行。然而，溶瘤Ad的全身注射在临床应用中由于显著的肝毒性和免疫原性而受到限制。为了克服这些问题，已经用许多聚合物物理或化学地工程化Ad以用于屏蔽Ad表面，实现延长的血液循环时间和降低的免疫原性以及肝毒性。在这篇综述中，我们描述和分类的特点，聚合物修饰的溶瘤腺病毒以下的每一个癌症治疗策略。最后，本文对各种聚合物涂层广告的特点、发展前景以及未来的研究方向进行了综述。
Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research.